Abstract
The mechanisms involved in the genesis of chronic obstructive pulmonary disease (COPD) are poorly defined. This area is complicated and difficult to model because COPD consists of four separate anatomic lesions (emphysema, small airway remodeling, pulmonary hypertension, and chronic bronchitis) and a functional lesion, acute exacerbation; moreover, the disease in humans develops over decades. This review discusses the various animal models that have been used to attempt to recreate human COPD and the advantages and disadvantages of each. None of the models reproduces the exact changes seen in humans, but cigarette smoke-induced disease appears to come the closest, and genetically modified animals also, in some instances, shed light on processes that appear to play a role.
Keywords: chronic obstructive pulmonary disease
chronic obstructive pulmonary disease (COPD) is an increasingly important cause of morbidity and mortality. COPD is now the fifth leading cause of death worldwide (109), and recent estimates suggest that the prevalence is as high as 9–10% of adults over age 40 (38, 131). In the developed world, cigarette smoking is by far the most important risk factor for COPD. Exposure to air pollution particles, occupational exposures to dusts and fumes (39), and, in the developing world, exposure to biomass fuels used for cooking is also believed to be etiological agents of COPD (38).
There are few animal models of COPD related to air pollution particles, dusts and fumes, and biomass fuels; most COPD models have either used cigarette smoke or other approaches, including genetic modifications to mice, believed to reproduce some of the mechanisms behind cigarette smoke. We have recently reviewed mechanistic studies of smoke-exposed animal models (16). In this paper, we will focus on the pros and cons of different COPD animal models.
The first question to ask in this context is what would constitute a perfect model of human COPD. This is not a simple question because human COPD consists of at least four anatomic lesions (further defined below): emphysema, small airway remodeling (including goblet cell metaplasia), chronic bronchitis, and pulmonary hypertension; a given patient may have any or all of these lesions. In addition, COPD patients may develop acute exacerbations that are believed to have an infectious basis. To further complicate matters, no matter which lesions are present, COPD develops and is slowly progressive over many years.
Because COPD is closely related to the underlying anatomy of the lung, a good animal model should have pulmonary anatomy similar to that of humans. The fundamental mechanisms behind COPD should be similar in animal models and humans. The ideal model would allow the investigator to produce the various different anatomic lesions just listed, all in a short period of time. Unfortunately, all of the known animal models meet only some of the above criteria, and even another human would probably not meet all of them, because, as noted above, there is considerable human to human variation in the pattern of COPD.
A variety of different approaches have been used to attempt to model COPD in animals, but there are some more general principles that will affect any COPD model, namely, 1) considerable differences among species in lung development and maturation; 2) differences among species in lung anatomy; and 3) susceptibility to injurious agents among species and strains within a species (discussed in Ref. 16).
Comparative Anatomy
Development and maturation.
The timing of pre- and postnatal development and maturation of the lung varies widely between species, and this problem needs to be taken into account when planning the initial exposure to any injurious agents.
The rat and mouse have no true alveoli at birth and develop all of their alveoli postnatally, with the majority of alveologenesis taking place between days 4 and 14 (90), whereas guinea pigs are well alveolated at birth and have only a small increase in numbers of alveoli as they age. Air space size normally increases with age, but this also varies with species. For example, guinea pigs (155) and rats (56, 96) have a progressive increase in size until 12 and 18 mo [although there appears to be some differences between strains (56)], and hamsters attain maximum size by 6 wk (reviewed in Ref. 61). Air space size change also varies among mouse strains, with BALB/c mice demonstrating increasing size up to 19 mo (61), whereas strain 129 has constant size after 4 wk (97).
The importance of recognizing lung maturation and growth patterns cannot be overstated. Administration of an injurious agent in the immediate postnatal period can interfere with alveolarization, and the enlarged air spaces may be falsely interpreted as emphysema. This is also true of genetically modified animals where the modification itself alters lung development in such a way that the animal has larger than normal air spaces (see Genetic and Genetically Modified Models of COPD).
Anatomic structure: bronchial tree.
The various animal species commonly used to model COPD differ significantly from each other and from humans in anatomy of the bronchial tree. Mice and rats have less extensive airway branching than do humans (93). Rodents do not normally have respiratory bronchioles; rather, a respiratory bronchiole-like type of metaplasia is induced by reaction to injury (112). This is considerably different from humans, where there are several generations of membranous and respiratory bronchioles. In humans, the membranous, and to a lesser extent, the respiratory bronchioles, are the targets of smoke-induced small airway remodeling, whereas the respiratory bronchioles are the initial site of injury in centrilobular emphysema.
Anatomic structure: airway epithelium.
In humans, the tracheal epithelium is pseudostratified and changes to a simple epithelial type in the subsegmental bronchi (55). The majority of the cells are ciliated and are present throughout the bronchial tree, gradually decreasing in proportion, but extending into the respiratory bronchioles (99). Goblet cells are plentiful in the large airways and progressively decrease until they are rare in the terminal bronchioles (99). This pattern is recapitulated in the guinea pig (Fig. 1) (55).
Fig. 1.
Comparison of tracheal epithelium from humans (A), guinea pigs (B), rats (C), and mice (D). In the human there are large numbers of ciliated cells and goblet cells, a pattern that is also found in the guinea pig. The rat has scant goblet cells, and the mouse has none. Ciliated cells are common in the rat but are present only in clusters (arrows) in the mouse. Bar = 100 μm; hematoxylin and eosin (H&E) stain.
Rats and mice tend to have ∼10-fold greater numbers of nonciliated bronchiolar cells in the small airways compared with humans (113, 166), and the cells vary ultrastructurally among species (113, 114). The tracheal epithelium of the mouse is a single columnar layer, whereas in the rat, the transition between pseudostratified and simple epithelium occurs at the hilum of the lung. In the mouse, goblet cells are rare in the trachea and almost totally absent in the membranous bronchioles; the majority of the tracheal epithelial cells are nonciliated Clara-like cells (105), although ciliated cells occur in large patches and account for ∼37% of the total cells (104). In the rat, the proportion of ciliated cells to nonciliated cells increases from upper trachea to bronchioles where they form ∼65% of total cells (55). Only a few goblet cells are present in the trachea and large airways and are generally not seen in the small airways.
Anatomic structure: bronchial glands.
Interestingly, this appears to be an area of controversy, and this issue is important, since human chronic bronchitis is characterized by hypertrophied and hyperplasic bronchial glands and excess mucus secretion. Although most authors agree that the size of the bronchial glands in laboratory animals is smaller than in humans, there is disagreement as to the number and positioning of glands in the various species (32, 54, 152) (Fig. 2). Despite these differences of opinion, it seems clear that bronchial glands are absent in the mouse and rabbit, almost absent in the hamster, present in the rat but concentrated in the upper portion of the trachea, and irregularly distributed in the guinea pig. Even when present, the number of glands in small animals is markedly less than large mammals, thus making small animals a very poor model for diseases such as chronic bronchitis.
Fig. 2.
Comparison of bronchial glands between human (A) and guinea pig (B). The human gland is large and well formed, whereas the guinea pig gland consists of a few acini only. Bar = 200 μm. H&E and alcian blue stain, respectively.
Anatomic structure: pulmonary arteries and veins.
In humans, the arterial and venous vasculature have definite courses and are separate from each other: the arteries follow the path of the airways, whereas the veins are present in the interlobular septa (Fig. 3). The main pulmonary artery and vessels larger than 1,000 μm in diameter are elastic in nature with short, branching, elastic fibrils arranged in laminae. Vessels between 500 and 100 μm are muscularized, with a tunica media present between two elastic laminae. Muscle becomes less apparent with decreasing size as the spiral of muscle becomes increasing separated until it disappears at the level of the distal arterioles. Pulmonary venules have a single elastic lamina and gradually acquire a muscular layer, the borders of which are generally ill defined as it also contains irregular elastic fibrils. At the level of the atrium, there may be a few cardiac muscle fibers.
Fig. 3.
A lung lobule in a human. Note the venous septa that bound the lobule (arrows) and the airway-artery unit in the center of the lobule. Lobules are not found in rodents. Bar = 1,000 μm; H&E stain.
In the rat, guinea pig, and mouse, interlobular septa are absent (94). The pulmonary artery branches follow the airways, but the pulmonary vein is independent and follows a separate course from the periphery of the lung to the hilum. The main and large pulmonary arteries are muscular rather than elastic, but there is a similar branching pattern and vessel distribution to that found in the human (45). In the guinea pig (94), the walls of the small arteries have intermittent areas of increased muscular thickness. In rodents, there is a wide variation in the point at which the arterial branches change from muscular to nonmuscular, with ∼50% of vessels adjacent to the terminal bronchioles and 80% of vessels adjacent to the alveolar ducts being nonmuscular (45). The arteries have a dense mesh of α-smooth muscle actin immunopositive cells which is organized in a spiral until the most distal vessels (106). Unlike humans, rodent pulmonary veins have a large amount of cardiac muscle at the hilum of the lung (106), and this is accompanied by a loose mesh of α-smooth muscle actin immunopositive cells, which decreases as the veins become smaller.
Anatomic structure: bronchial arteries.
The bronchial arterial supply is known to be important in the overall lung reaction to injury, and thus anatomy and distribution are important in any animal model. There is considerable person-to-person variation in the human bronchial artery supply (99, 135). These arteries invest the bronchi and extend throughout the length of the bronchial tree, with communication between the bronchial and pulmonary circulations in the terminal respiratory unit. In mice (116), a bronchial artery supply exists, and there are interconnections between the two vascular systems at the level of the capillaries. Rats have a relatively similar system to humans, but with slightly different vascular derivations (135).
Lung Mechanics
A careful quantification of air space size utilizing morphometry should be mandatory to define “emphysema” as a first step to assess the response to the exposure or manipulation used in the intended animal model. However, as noted by Henson and Vandivier (44), it is remarkably easy to induce alveolar enlargement with a very wide variety of manipulations in the mouse, the most widely used animal as a model for emphysema, and this raises the question of how specific such findings might be, particularly since many such manipulations appear to be interfering with lung growth or producing abnormal lung development (see Elastase Emphysema Model and Genetic and Genetically Modified Models of COPD).
Another approach is to use pulmonary function to define emphysema on the basis that, while pulmonary function tests are less sensitive than morphometry and thus may detect only more severe degrees of airways remodeling or parenchymal destruction, they demonstrate meaningful physiological changes. Although mild emphysema may have normal lung mechanics, more marked emphysematous lung destruction ought to have abnormal lung mechanics. The most specific function test representative of emphysema is loss of elastic recoil, determined from pressure-volume (P-V) curves (increased compliance or decreased elastance).
This issue is nicely illustrated in the following papers. Foronjy et al. (25) found that long-term cigarette smoke exposure in two strains of mice (CBA/JXC57BL/GJ) and A/J resulted in a 17% and 32% increase in mean linear intercept (Lm), but no change in lung compliance. Furthermore, neither strain had a decrease in lung elastin by immunostaining or by elastin assay methods. In contrast, Cavarra et al. (14) and Takubo et al. (137) found that the pallid mouse, a strain with low levels of α1-antitrypsin, developed significant air space enlargement, had a 19% decrease in lung elastin content, and significant increases in compliance (Fig. 4), thus more closely resembling human emphysema. Similar results have been found by us in the AKR/J mouse strain (36) and in the guinea pig (18, 155).
Fig. 4.
A: partial pressure-volume (P-V) curves between 3 and 9 cmH2O pressure in the NZW Lac/J (resistant strain), C57 BL6/J (moderately susceptible strain), and AKR/J (super-susceptible strain). [From Takubo et al. (137).] Pallid P-V curves have been added to illustrate the susceptible strain from our prior publication. SJ/L and A/J curves were superimposable to the C57BL/6/J P-V curves. *P < 0.001; **P < 0.0001. B: P-V curves in an emphysematous mouse (A) and a control (B). Curves were done in the traditional way inflating the lung to 30 cmH2O and measuring pressure at the airway opening. The maneuver was done both in step-wise, no flow, and slow deflation methods. Both curves are superimposable. The Flexivent machine was used.
Which of these approaches is “correct”? There is no simple answer to this question; at the present time, there are no definitive studies that illustrate a direct correlation of air space enlargement and compliance or a level of air space enlargement beyond which alterations of compliance would be expected, and it is unclear whether more marked emphysema (as defined in this way) is a better approximation to human disease mechanisms than less marked emphysema. Furthermore, the marked laboratory-to-laboratory variations in response in even the same (notional) mouse strains make comparisons almost impossible.
As a general rule, the greater the severity of emphysema, the greater the chance that a protective intervention is really significant, rather than just a minor experiment-to-experiment variation, but this idea must be tempered by the realization that none of these models translates to human disease in any direct fashion, and an intervention that ameliorates fairly mild emphysema might turn out to be mechanistically important. For example, there is increasing evidence for the importance of immunological reactions in the genesis of emphysema (1). In their investigations relating to the role of CD4 and CD8 T-lymphocytes in cigarette smoke-induced emphysema, Maeno et al. (81) found a 19–21% increase in air space size in wild-type C57/Bl/6J mice with a respective increase of 19% and 0.4% in CD4−/− and CD8−/− cell-deficient mice. One must ask, therefore, whether the lack of lung mechanics invalidates the importance of this mechanistic data.
Normally lung mechanics in mice and other rodents are performed at the end of the experiment with the animal alive, anesthetized, paralyzed, and with the chest opened or closed. Mechanics measurements done in dead animals are not as accurate or reproducible, and measurements deteriorate as times from death increase. Lung mechanics and other pulmonary function tests can be easily measured in guinea pigs (155) or other large rodents utilizing a body plethysmograph, a tracheal canula, and an esophageal tube to obtain P-V curves, FRC, and other lung volumes. Flows can also be measured by rapidly deflating the lungs from TLC applying an airway pressure of −50 cmH2O. Measurement of lung mechanics can also be performed in mice, although it is technically more difficult, and we and others have used a small animal ventilator, Flexivent Scireq (Montreal, Canada), equipped with the necessary hardware and software to accurately measure elastance, resistance, and tissue resistance along with inspiratory and expiratory P-V curves.
Lung mechanics can also be measured in live rodents, including mice, with the expectation of recovery after the measurements (nonterminal event). After anesthesia, the animals can be (relatively) easily intubated and subsequent measurements obtained (11, 140). The obvious advantage of this technique is that it allows the documentation of functional changes over time in the same animal (161).
Vendors
There are large numbers of animal suppliers available in North America, Europe, and Asia; regular strains, transgenics, genetic models, etc., are available through these suppliers. The web site www.rodentia.com is a useful and informative starting point where most of the best suppliers of mice are listed with their www portals. It should be kept in mind that at least for the “regular” nonmodified strains of mice, differences in response to specific manipulations in the same strain from different suppliers may occur. In one of our laboratories (M. Cosio), we have identified changes in response to a manipulation (cigarette smoke) in the same strain from the same provider, after a colony had to be restarted from frozen embryos.
Cigarette Smoke Exposure Model of COPD
Given its position as the predominant cause of COPD, animal models using smoke exposure would appear to be the logical choice for investigation, but it is only relatively recently that such models have been created. We have recently reviewed the findings and conclusions from smoke-induced animal models of COPD (16); here we will consider only the advantages and limitations of such models.
Methods of smoke exposure.
There are a variety of commercial and home-built smoking machines that have been used with animal models; some systems use nose-only exposures and some whole body exposures. There is a theoretic negative to whole body exposure in that the animals may ingest nicotine or tar substances when cleaning their fur. However, Mauderly et al. (92) showed that although this was a factor, there was less carboxyhemoglobin in the animals given whole body exposure, and these animals had less weight loss than did animals given a nose-only continuous or intermittent types of exposure.
When establishing any smoke exposure model, measurement of either serum cotinine (a nicotine metabolite) or blood carboxyhemoglobin (COHb) is useful as a method of confirming the relative amount of smoke exposure. In our guinea pig nose-only exposure model, we find an acute post-smoke carboxyhemoglobin of 15–20% and a chronic blood carboxyhemoglobin level of ∼5%, the latter comparable to that seen in many human smokers. In humans, the dissociation of carboxyhemoglobin when breathing air results in a half-life of ∼4–6 h; animal data are not available, although COHb levels rapidly decline after smoke cessation (43). A serum cotinine level of 200–250 ng/ml is equivalent to a mild to moderate human cigarette smoker (31, 43, 103, 127).
Choice and limitation of species.
All modern studies of cigarette smoke-induced COPD have used small laboratory animals including mice, rats, and guinea pigs. Guinea pigs offer numerous advantages, including easily recognizable emphysema, more marked small airway remodeling than mice, and the development of considerable goblet cell metaplasia in the airways. Mice and rats develop only minimal goblet cell metaplasia in the smaller airways, although rats do demonstrate metaplasia in the larger airways. As well, it is easy to perform extensive pulmonary function evaluations along with cardiac catheterization in guinea pigs (155, 162). Their main disadvantages are cost, the lack of tools for performing molecular studies, and the limited number of commercial antibodies that cross react with guinea pig proteins.
In our experience, rats are a poor model for COPD. In most investigators' hands, they develop minimal disease, or, if smoked too heavily, develop nonspecific particle overload effects (see, for example, Ref. 132).
Most recent models of COPD have used mice. Detailed pulmonary function is technically difficult, although possible, in mice (36, 84, 137), but P-V curves and compliance changes can be measured fairly easily. Mice offer the advantages of low cost, extensive gene/protein sequence/antibody availability, and, most important, the availability of numerous naturally occurring mouse strains with different reactions to smoke and the ability to produce animals with genetic modifications that shed light on specific processes within COPD.
One point that confounds all of the literature on cigarette smoke-induced models is laboratory-to-laboratory variations in response. Even when the same mouse strain is used, different laboratories get quite different degrees of disease. For example, Churg et al. found increases in mean air space size (Lm) of 37% (20) and 38% (19) after 6 mo of exposure using C57Bl/6 mice, but Cavarra et al. (14) and Guerassimov et al. (36) reported increases of only 14% and 13% in the same strain. In part, this problem is caused by differences in the strains from different providers, technical differences in morphometric techniques, the use of different smoking systems (nose only vs. whole body, smoke concentration, smoke time, and frequency), and by differences in the types of cigarettes smoked. It is our impression that currently available cigarettes (such as Kentucky 2R4F or 2R5F) cause considerably less emphysema than older ones (such as Kentucky 1R1 or 2R1), and this is a serious problem, both in terms of producing disease and particularly in terms of examining interventions, since one never knows whether interventions that ameliorate small increases in air space size would really be effective with more severe disease.
Cigarette smoke-induced models of emphysema.
Emphysema is the anatomic lesion that, historically, has attracted the most attention in patients with COPD, and, similarly, has been the focus of most animal models (Figs. 5, 6). Except for α1-antitrypsin-deficient pallid mice (14, 137), models of smoke-induced emphysema typically produce dilated alveolar ducts; these changes progress with increasing amount of smoking and are, anatomically, similar to a mild form of the centrilobular emphysema commonly found in human cigarette smokers, but the overt tissue destruction seen in humans is much harder to demonstrate in animals (14). The parenchyma between the dilated alveolar ducts is abnormal, with increases in size and number of the pores of Kohn that connect adjacent alveoli (154), a phenomenon also found in the lungs of human cigarette smokers (21, 65, 101). There is evidence that women are more susceptible to the effects of smoke than men (29, 70, 85, 148) and female A/J mice develop emphysema earlier than male A/J mice (84).
Fig. 5.
Example of centriacinar emphysema in a human. Note that the respiratory bronchiole and alveolar duct complex is distorted and destroyed. Aggregates of pigmented alveolar macrophages can be found (arrow). Bar = 1,000 μm; H&E stain.
Fig. 6.
Example of a guinea pig emphysema model induced by exposure to cigarette smoke for 6 mo. A shows a representative control lung, whereas B shows a representative smoke-exposed lung with an overall increase in air space size of ∼43%. Bar = 200 μm; H&E stain.
The lesions produced in laboratory animals can be subtle, even on microscopic examination; thus morphometric analysis is required to assess the degree of damage. Measurements of air space size (Lm) or surface-to-volume ratio (Sv) (reviewed in Ref. 141) and sometimes destructive index (14) are used for this purpose. Arguably, it would be better to measure only alveolar ducts, since that is the major site of the abnormality, and such measurements do provide more marked differences between smoke-exposed and control animals (see Ref. 19, for example). However, measurements of alveolar duct air require greater morphometric effort (137) and are not widely used.
Smoke-exposed guinea pigs and mice show physiological changes that mimic mild COPD in humans (18, 36, 84, 137, 155). The residual volume increases as does functional residual capacity and total lung capacity. The P-V curve is shifted upwards and to the left, compliance increases, and the flow volume curve demonstrates diminished flow at the lower lung volumes. Ratios of FEV/FVC also decrease. These abnormalities progress with increasing length of smoke exposure (155).
Cigarette smoke-induced small airway remodeling.
Small airway remodeling (increased matrix components, inflammatory cells, and goblet cell metaplasia in the airway wall with luminal narrowing, distortion, and obstruction by mucus) is now accepted as an important cause of airflow obstruction in human smokers (46, 47, 98, 107, 156). These changes increase with increasing Global Initiative on Chronic Obstructive Lung Disease (GOLD) stage (47). Excess mucus secretion is also thought to be important in the pathogenesis of acute exacerbations of COPD (reviewed in Ref. 6).
In animals, early smoke inhalation studies demonstrated increases in the numbers of goblet cells in the proximal trachea in a variety of species (7, 42, 57, 69, 108, 117), but there is a considerable species effect and a large degree of variation in the degree of metaplastic change. In the guinea pig model, chronic smoke exposure induces secretory cell metaplasia in the small airways (158), and similar to humans, smoking cessation reduces the degree of metaplasia (160).
Little attention has been paid to small airway wall remodeling in animal models, probably because these changes are too subtle to be reliably picked up by casual microscopic observation, and some deny their existence (84). Nonetheless, morphometric analysis confirms that the small airway walls are thickened in both mice and guinea pigs after long-term smoke exposure (10, 17, 18, 159). Most of the increased wall area is composed of collagen and fibronectin, and smooth muscle is not increased (10, 17, 95, 159). There is also increased collagen fiber alignment and more dense packing of the fibers, findings that imply increased mechanical stiffness in the airway wall (159). In guinea pigs, the severity of changes in collagen structure correlates negatively with PEF and FEV0.1/FVC, and positively with airway resistance. Physiological lung volumes correlate with air space size, but RV and TLC also are related to airway wall thickness (159).
Small numbers of lymphocytes are found around the bronchioles in mice and guinea pigs and are analogous to the lymphoid aggregates seen in humans. Smoke causes quite marked increases in the number and size of these aggregates (9, 10, 146).
Cigarette smoke-induced vascular remodeling and pulmonary hypertension.
In subjects with established pulmonary hypertension related to COPD, there is intimal thickening and muscular hyperplasia in the normally muscularized vessels adjacent to the bronchioles and increased muscularization of the usually partially muscularized arteries adjacent to the alveolar ducts (reviewed in Refs. 3, 157).
In Hartley strain guinea pigs, chronic cigarette smoke exposure produces about a 25% increase in pulmonary arterial pressure (160, 162), which, interestingly, appears after 1 mo of smoke exposure and does not progress. Similar to human disease, PHT in guinea pigs is associated with muscularization of the small, normally poorly muscularized pulmonary arteries adjacent to the alveolar ducts (162). Increased pulmonary artery pressure (∼30%) has also been reported in one study of smoke-exposed rats (72) but thus far has not been reported in mice. Vascular remodeling, however, has been reported in mice, and there are apparent strain differences in the severity of remodeling (100).
Conclusions regarding smoke-induced models.
Cigarette smoke exposure to animals appears to be the best approximation to human COPD: a form of emphysema, small airway remodeling, and pulmonary hypertension can be produced (Table 1). Mucus hypersecretion is more problematic. One important downside to these models is that production of either emphysema or small airway remodeling takes months of smoke exposure (usually on the order of 6 mo) and thus is an expensive and time-consuming proposition. However, the most important limitation of smoke models, no matter what species is selected and no matter how long animals are smoked, is that the disease they produce is mild, probably equivalent to human GOLD (24, 115) stage 1 or 2 disease. In humans, the majority of morbidity and mortality occurs in patients with GOLD stage 3 or 4 disease (FEV1 <50% predicted), but the type of severe emphysema or severe small airway remodeling found in GOLD stage 3 or 4 patients simply cannot be reproduced in animals using smoke exposure. Last, in advanced GOLD stage patients, COPD frequently progresses even after the patient stops smoking, but this phenomenon has not been reproduced in animal models, where cessation of smoke exposure leaves the animals with stable, nonprogressive emphysema, and goblet cell metasplasia regresses (160).
Table 1.
Pros and cons of cigarette smoke-induced model of COPD
| Pros: |
| Induced by same insult as in humans |
| Produces emphysema, airway remodeling, and vascular remodeling/pulmonary hypertension in selected species |
| Produces physiological alterations similar to humans |
| Cons: |
| Does not produce the severe disabling disease seen in humans |
| Requires several months of exposure |
| Lesions do not appear to progress after cessation of smoke exposure |
Apoptosis as a Model of COPD
There are several excellent recent reviews of this subject (144, 145, 151, 163). The idea that emphysema occurs as a failure of the lung maintenance and repair system follows from studies that have induced apoptosis by interference with vascular endothelial growth factor (VEGF) (60) or its receptor (VEGF-R) (139) or the VEGF-VEGFR complex (88). Apoptosis generally involves activation of the caspase cascade and can be induced by intratracheal instillation of activated caspase-3 as well as other agents (2). Activation of ceramide, an upstream regulator, (111) will also induce apoptosis.
These models induce air space enlargement in a very short period of time (Fig. 7) but do not appear to affect the airways. Inhibition of VEGF receptors sufficient to induce air space enlargement also causes pruning of the vascular bed and pulmonary hypertension (60, 138, 143, 150), with increased muscularization of the small pulmonary arteries.
Fig. 7.
Example of a mouse apoptosis emphysema model induced by installation of active caspase-3. A shows a representative control lung. B shows a representative image from lungs 48 h after installation of active caspase-3, with an overall increase in air space size of ∼4%. The arrowheads indicate enlarged air spaces. Bar = 50 μm; H&E stain. [From Petrache et al. (110).]
Conclusions.
Although inhibition of the VEGF system appears to result in relatively permanent air space enlargement, instillation of a single dose of activated caspase-3 produced initial air space enlargement followed by diminution of air space size within 15 days (2). Thus far, none of these models has been shown to be associated with matrix breakdown, an event that is believed to be central to the pathogenesis of emphysema (reviewed in Ref. 16), nor have they been shown to reproduce the physiological changes of emphysema. Finally, it is important to recognize that apoptosis has only been found to be increased in human lungs with severe emphysema, and analysis of the smoke-exposed mouse or guinea model has shown inconsistent results, with no significant increases in the number of apoptotic cells in some studies (Churg A and Wright JL, unpublished data) (25), whereas one study found focal areas of apoptosis, but only in DBA/2 and not in C57Bl/6 mice (5) (Table 2).
Table 2.
Pros and cons of apoptosis model of COPD
| Pros: |
| Short-term model |
| Induces enlarged air spaces (? “emphysema”) and vascular remodeling |
| Cons: |
| “Emphysema” not permanent |
| Apoptosis not consistently present in animal models of cigarette smoke-induced emphysema |
| Airway remodeling not present |
Elastase Emphysema Model
The current generally accepted hypothesis of cigarette smoke-induced emphysema is the protease-antiprotease hypothesis. This hypothesis developed out of two key observations: first, Laurell and Eriksson (71) reported that patients who were deficient in α1-antitrypsin developed early emphysema. Second, in 1965, Gross et al. (34) described the induction of emphysema in rats by instillation of the plant protease, papain. These observations led to the idea that emphysema develops as a result of a cigarette smoke-mediated influx of inflammatory cells into the lower respiratory tract with resulting release of proteases that destroy the parenchymal matrix.
The protease-antiprotease hypothesis was in large measure formulated from experiments in which emphysema was caused by administration of elastolytic enzymes, either by intratracheal instillation or aerosol inhalation; these models are currently referred to by the generic term “elastase emphysema” (Fig. 8). A variety of enzymes have been used for this purpose (52, 53, 74, 75), and one of the key findings in this regard was that only enzymes that could degrade intact elastin-produced emphysema; collagenases by themselves were ineffective (75, 136). These findings led to the current belief that destruction of the elastin framework of the lung is the fundamental pathological abnormality in emphysema.
Fig. 8.
An example of a murine emphysema model induced by elastase. The figure contrasts a representative control lung to a representative elastase-treated lung, with an overall increase in air space size of ∼60%; H&E stain. Photos courtesy of Dr. S. Shapiro, University of Pittsburgh, PA.
While papain was used in initial studies, its elastase activity depends on its purity and source (75). Almost all recent studies have used either porcine pancreatic elastase (PPE) or human neutrophil elastase (HNE). PPE offers the advantages of being inexpensive and easy to obtain. Consistent quality human neutrophil elastase is now available but considerably more expensive. Experiments using crude preparations of human neutrophils first and then purified HNE were in fact instrumental in arriving at the notion that smoke-evoked inflammatory cells release elastolytic proteases that can destroy the lung (52, 53, 75). From a practical point of view, it is important to note that PPE and HNE do not have the same proteolytic spectrum; they have different primary endogenous inhibitors [α1-antitrypsin for HNE, but α2-macroglobulin for PPE, although α1-antitrypsin is also effective (133)], and, even more important, a particular exogenous inhibitor may not inhibit both of these enzymes (for example, see Refs. 67 and 68 and see below). This is a crucial point to bear in mind if one is attempting to show efficacy of a novel inhibitor.
A wide variety of animals have been used in the elastase emphysema model (52, 75). Much of the early work, and some recent work, was done in hamsters, based initially on the empiric observation that hamsters appeared to develop more severe disease. The reason for this turns out to be that hamsters normally have relatively low levels of α1-antitrypsin (52, 75). Conversely, several investigators showed that administration of α1-antitrypsin or normal serum but not serum from persons deficient in α1-antitrypsin prevented or ameliorated elastase emphysema (58, 86); this observation again was important in formulating the protease-antiprotease hypothesis.
Table 3 lists pros and cons of the elastase emphysema model. The major advantages are that emphysema can be rapidly induced by a single treatment with an inexpensive reagent, which makes it vastly cheaper and easy to run than a 6-mo smoke exposure. Disease severity can be controlled by selection of enzyme dose. As opposed to smoke-induced emphysema, it is relatively easy to produce severe emphysema with elastase instillation, and this facilitates detection of pulmonary function abnormalities, particularly when evaluating the effects of an inhibitor or intervention such as lung volume reduction surgery or abnormalities in connective tissue elasticity (15, 51). Biochemical and in situ hybridization studies have shown that over time there is increased synthesis of elastin and to a lesser extent collagen (77), making the model a candidate for studies on alveolar repair and regeneration [however, studies using all trans retinoic acid and/or bone marrow cell instillation or various colony-stimulating factors to attempt to drive repair are contradictory (49, 50, 76, 102, 164)]. But probably the most important current reason to use the elastase emphysema model is the situation where an intervention requires scarce/expensive resources that would not be feasible for a 6-mo smoke exposure. For example, Houghton et al. (48) recently showed that antibodies against elastin fragments ameliorated the inflammatory response and emphysema in mice given PPE.
Table 3.
Pros and cons of elastase model of COPD
| Pros: |
| Single treatment (as opposed to 6 mo of smoke)/economic and easy |
| Rapid onset |
| Can produce severe disease depending on dose |
| Progressive in some hands |
| Easy to measure functional changes |
| Good choice when dealing with scarce resources where impossible or too expensive to run a 6-mo smoke |
| Possibly relevant to certain aspects of regeneration of elastin network |
| Cons: |
| Choice of enzyme, animal species, age of animals, dose protocol crucial for consistent results |
| Neutrophil elastase and porcine pancreatic elastase appear to act somewhat differently |
| Relevance to mechanisms that actually occur with smoke exposure is unclear |
| Elastase emphysema does not model all the very complicated events seen with smoke |
| Relevance of therapies/interventions even less clear than with animal models of smoke exposure |
The major disadvantages of the elastase emphysema model center around two related problems: 1) although both elastase and cigarette smoke produce emphysema through proteolytic attack on the lung matrix, the detailed mechanisms of this process are probably very different; and 2) the mechanisms behind elastase emphysema are not clear. Both light microscopic and electron microscopic studies (52, 66, 165) show rapid loss of elastin after enzyme instillation, but the disease progresses (depending somewhat on animal and dose) long after elastase activity can no longer be detected. In fact, the measured half-life of HNE or PPE in this model is ∼45–50 min (133). It has been suggested that progression is caused by enzyme bound to the matrix and not detectable with conventional assays, but a late intervention (day 20) with an elastase inhibitor did not prevent progression (79), which the authors interpreted to mean that other processes are involved. Single dose elastase inhibitors appear to work when given immediately before or immediately after elastase administration, but are not effective if given 4 or 8 h later (35, 63, 134). However, two synthetic serine elastase inhibitors [ICI 200,800 and ICI 200,855 (153)] prevented both PPE and HNE driven emphysema when started 24 h after enzyme dosing and continued on a daily basis. Other novel elastase inhibitors/elastin protectors (13, 67, 80) also provide some degree of protection.
In fact, the model is certainly more complicated than pure elastase attack. Elastase emphysema itself is subtly different from human emphysema, with pure alveolar enlargement predominating in elastase emphysema and increased alveolar wall destruction (measured by the destructive index) in human (23) and to some extent in murine smoke-induced emphysema (84). Soon after enzyme administration, there is both hemorrhage and an inflammatory exudate which includes neutrophils and macrophages in the lower respiratory tract, and there is upregulation of a variety of proinflammatory mediators such as TNFα, IL-1β, IL-6, and IL-8 (28). It has been claimed that there are increased numbers of apoptotic parenchymal cells (126, 164), but these studies have only used TUNEL staining and hence are inconclusive. Inflammatory processes clearly play an important role since mice lacking both TNFα and IL-1 receptors are ∼80% protected against PPE-driven emphysema and inflammation (78), as are mice overexpressing CuZnSOD (26) and mice given the anti-inflammatory agent HO-1 by adenoviral transfer (129). Elgin-C, which inhibits rat NE but not PPE, was protective against PPE-driven emphysema, supporting a role for endogenous elastases (68). On the other hand, a broad spectrum MMP inhibitor decreased emphysema but not inflammation (8).
One further practical complication is that animal age appears to be important, but the literature is contradictory, with claims that either younger or older animals are more resistant to PPE (33, 59, 87).
Conclusions regard the elastase emphysema model.
Overall, these findings indicate that although elastase emphysema is simple to produce, the model is not mechanistically simple at all. At best, elastase emphysema is a screening technique for mechanisms and/or interventions that could apply to human smokers; however, this approach is fairly far removed from smoke exposure and in our opinion is generally inferior to animal models using smoke exposure.
Starvation-Induced Model of COPD
In humans, chronic malnourishment or actual starvation appears to be associated with emphysema-like alterations of the lung parenchyma (reviewed in Ref. 22). Starvation models in rats have varied in the amount of reduced feeding and also have varying degrees of alteration in lung structure and physiological changes (119, 121–125). Alterations of lung mechanics were generally characterized by a decrease in lung volume related to transpulmonary pressures, and in one study (125), the shift in the saline P-V curve was accompanied by significant reductions in elastic recoil, and chord compliance (slope of the straight line between 80 and 40% maximal lung volume) was increased by 47%, with a 53% increase in air space size. Mechanical changes reverted to normal with refeeding (123), and although bulk lung hydroxyproline also reverted to normal, elastin remained decreased (122). Cycles of starvation and refeeding resulted in overall findings similar to those above, but there was also a decreased alveolar surface area interpreted as a decreased number of alveoli (120). Calorie depletion accompanied by protein depletion showed the unexpected finding of less severe emphysema than in those animals with similar caloric intake that included protein. All of the calorie-restricted groups had smaller lung volumes and fewer alveoli than did the control group indicating that the effect of starvation is a lack of lung growth.
A comparison between starvation (45% loss of body wt) and elastase-induced emphysema showed considerable differences between the two models (41). While elastase-induced emphysema mimicked human emphysema, with increased lung volumes and subdivisions of lung volume, a shift to the right of the P-V curve, and reduced expiratory flow rates, the P-V curve in the starvation group was shifted to the right, the lung volumes were not increased, and there was no decrease in airflow. Both groups had enlarged air spaces suggesting that the two models may represent lung destruction in the case of elastase emphysema and alterations of lung growth in the case of starvation emphysema. But recent studies in mice (89, 91) have questioned this explanation since alveoli appear to be lost early in calorie restriction and gained after refeeding. Starvation appears to stimulate caspase gene expression and Fas death receptor expression, with depression of cell replication, while refeeding increases cell replication, DNA synthesis, and increased RNA expression for a large number of cell replication-related genes.
Conclusions regarding starvation models.
Starvation models are relatively short term in duration and produce enlarged air spaces, but they do not produce the physiological changes of emphysema and more likely represent models of abnormal lung growth or abnormal repair (Table 4). No airway or vascular alterations have been described.
Table 4.
Pros and cons of starvation model of COPD
| Pros: |
| Short-term model with relatively consistent results |
| Cons: |
| Does not match human physiological changes |
| May represent a model of abnormal lung maintenance/repair/abnormal lung growth |
| Ethical considerations of induction of 45% weight loss by starvation |
LPS-Induced Models of COPD
LPS is a glycolipid component of gram-negative bacterial cell walls and is used because of its proinflammatory effects. It is present as a contaminant in cigarette smoke, air pollution, and organic dusts. In humans, chronic exposure to LPS-laden dusts results in decreased lung function (reviewed in Ref. 147). In the acute model, LPS induces a mixed inflammatory reaction with increases in neutrophils (8) and increases in BAL TNFα and IL-1β, and increases in MMP-9 and MMP-12 (73, 147) (Fig. 9A). In mice (147), repeated intratracheal LPS installations induces marked inflammation with predominately CD4+ T cell lymphoid aggregates around the airways and large vessels, and an increase in intra-epithelial bronchiolar epithelial cell lymphocytes. This was associated with large numbers of intra-alveolar macrophages. Cytokine mRNA profiles showed increases in TNFα, IFNγ, and IL-18, a finding that persisted after exposures ceased.
Fig. 9.
A: example of a mouse subacute LPS model induced by exposure to LPS for 1 h per day for 5 days. Note the inflammatory reaction in the air spaces and interstitium. H&E stain. Magnification, ∼×10, courtesy of Dr. M. K. Lee, Battelle Science and Technology, Richland, WA. B: example of a hamster emphysema model induced by installation of LPS twice per week for 4 wk and death after 28 days after the final installation. Emphysematous areas are surrounded by relatively normal areas with an overall increase in air space size of ∼30%. The arrows point to iron depositions. [From Rudolphus et al. (118).]
With chronic administration over several weeks, LPS instillation produces enlarged air spaces (Fig. 9B) and remodeled airways with thickened walls and increased goblet cells in the larger airways in mice, guinea pigs, and rats (40, 142, 147). In the guinea pig model (40), progressive exposures resulted in a decline in specific airway conductance and an increased duration of bronchoconstriction after exposure. These changes resemble human emphysema and small airway remodeling (albeit again relatively mild) and may be driven by mechanisms that are somewhat similar to human disease; however, these mechanisms are poorly defined.
Conclusions regarding LPS models.
LPS instillation is a short term model which produces some anatomic features of human COPD, but the inflammatory infiltrate differs from that in smoke models, suggesting different mechanisms (Table 5). Probably the most important use of LPS is to mimic acute exacerbations, either given alone or given to animals also receiving cigarette smoke. The topic of models of acute exacerbation has been recently reviewed in Refs. 30, 62, 83.
Table 5.
Pros and cons of LPS model of COPD
| Pros: |
| Short-term model with airway and parenchymal changes, and inflammatory cytokine upregulation |
| May be helpful in investigations of exacerbation |
| Cons: |
| Inflammatory infiltrate not analogous to that found with cigarette smoke |
| Unclear whether mechanisms involved recapitulate those of cigarette smoke-induced lesions |
Genetic and Genetically Modified Models of COPD
Much of the recent literature on COPD models has used either naturally occurring mouse strains or laboratory-produced animals that either overexpress or lack particular genes. Several excellent reviews of such models are available (12, 82, 128, 144, 149), and we will only comment briefly here on their advantages and disadvantages.
Different naturally occurring mouse strains show markedly different responses to smoke which depend in part on naturally occurring levels of antioxidant and antiprotease protection and in part on genetic factors that control the innate and acquired inflammatory response to smoke (14, 81). Different strains have a variety of genetic differences, and thus one usually cannot attribute different responses to an insult such as smoke to a single gene change, as is possible with man-made genetically targeted animals (there are exceptions to this rule, however, such as pallid mice that are α1-antitrypsin deficient) (14, 137).
Genetically altered animals allow investigation of the effects of a specific gene/protein on all of the different anatomic lesions of COPD and potentially also are useful in designing therapeutic agents. Most attention has been directed to models of emphysema, with much less information available about small airway remodeling (64). All such models need to be interpreted very cautiously, because constitutive overexpression or knockout of a particular gene can interfere with lung development and lung growth, resulting in enlarged air spaces that superficially appear to represent emphysema but are really developmental abnormalities. Conversely, constitutive expression of a gene might also lead to accelerated aging, and accelerated senescence mice are known to develop emphysema (130).
Several different approaches have been taken to try and get around the issue of developmental abnormalities. Some constitutive transgenic models of emphysema have concentrated on selection of strains in which transgene expression is present at a very low level and disease only appears to manifest late in adulthood (27). Such models provide support for the importance of the gene in question but by definition cannot rule out either subtle developmental or aging abnormalities.
Inducible models generally use constructs in which feeding of doxycycline drives the gene in question with a lung-specific promoter. This approach in theory prevents problems with developmental or premature aging effects. However, there may be small amounts of “leakage” of the transgene even in the absence of doxycycline, and it has been reported that the reverse tetracycline-transactivator gene that is used to create inducible constructs can itself can produce enlarged air spaces (130). As well, doxycycline is a matrix metalloprotease inhibitor that inhibits MMPs such as MMP-2 and MMP-9 that are thought to play a role in COPD (37). Thus careful controls are essential in interpreting such experiments. Last, it is important to remember that overexpression of a particular gene may lead to production of huge amounts of protein, and there is no guarantee that “pharmacological” doses of a particular protein act in a similar fashion to physiological doses.
Conclusions regarding models using genetically altered animals and different naturally occurring strains.
These problems notwithstanding, genetically modified animals and naturally occurring mouse strains have produced a wealth of data, either by themselves or when such animals are exposed to cigarette smoke. We have recently reviewed the topic of smoke-induced models and the mechanisms behind such models in this journal (16). How closely these models mimic the pathogenesis of human disease is still open to question (4).
Conclusions
A variety of quite widely differing types of animal models has been created to attempt to reproduce human COPD. None of them succeeds perfectly in this attempt, and all have problems. Nonetheless, cigarette smoke-induced models of either naturally occurring or man-made animal strains appear to be the best choice for most purposes if one has the resources and patience to carry out the very long exposures required. Elastase emphysema has a limited role, particularly when resources are scarce. Models that examine failure of lung maintenance or failure of repair will probably be important in understanding the pathogenesis of emphysema, but as yet don't clearly approximate events in the human lung.
GRANTS
This work was supported by Canadian Institutes of Health Research Grants 42539 and 81409, a grant from the Heart and Stroke Foundation of British Columbia and Yukon, and the Lloyd Carr-Harris Foundation.
REFERENCES
- 1.Agusti A, MacNee W, Donaldson K, Cosio M. Hypothesis: does COPD have an autoimmune component? Thorax 58: 832–834, 2003. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 2.Aoshiba K, Yokohori N, Nagai A. Alveolar wall apoptosis causes lung destruction and emphysematous changes. Am J Respir Cell Mol Biol 28: 555–562, 2003. [DOI] [PubMed] [Google Scholar]
- 3.Barbera JA, Peinado VI, Santos S. Pulmonary hypertension in chronic obstructive pulmonary disease. Eur Respir J 21: 892–905, 2003. [DOI] [PubMed] [Google Scholar]
- 4.Barnes PJ Unexpected failure of anti-tumor necrosis factor therapy in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 175: 866–867, 2007. [DOI] [PubMed] [Google Scholar]
- 5.Bartalesi B, Cavarra E, Fineschi S, Lucattelli M, Lunghi B, Martorana PA, Lungarella G. Different lung responses to cigarette smoke in two strains of mice sensitive to oxidants. Eur Respir J 25: 15–22, 2005. [DOI] [PubMed] [Google Scholar]
- 6.Berge S, Wedzicha JA. COPD exacerbations: definitions and classifications. Eur Respir J 21, S41: 46S–53S, 2003. [DOI] [PubMed] [Google Scholar]
- 7.Bernfeld P, Homburger F, Soto E, Pai KJ. Cigarette smoke inhalation studies in inbred Syrian Golden hamsters. JNCI 63: 675–689, 1979. [DOI] [PubMed] [Google Scholar]
- 8.Birrell MA, Wong S, Dekkak A, DeAlba J, Haj-Yahia S, Belvisi MG. Role of matrix metalloproteinases in the inflammatory response in human airway cell-based assays and in rodent models of airway disease. J Pharmacol Exp Ther 318: 741–750, 2006. [DOI] [PubMed] [Google Scholar]
- 9.Bracke KR, D'hulst AI, Maes T, Demedts IK, Moerloose KB, Kuziel WA, Joos GF, Brusselle GG. Cigarette smoke-induced pulmonary inflammation, but not airway remodelling, is attenuated in chemokine receptor 5-deficient mice. Clin Exp Allergy 37: 1467–1479, 2007. [DOI] [PubMed] [Google Scholar]
- 10.Bracke KR, D'hulst AI, Maes T, Moerloose KB, Demedts IK, Lebecque S, Joos GF, Brusselle GG. Cigarette smoke-induced pulmonary inflammation and emphysema are attenuated in CCR6-deficient mice. J Immunol 177: 4350–4359, 2006. [DOI] [PubMed] [Google Scholar]
- 11.Brown RH, Walters DM, Greenberg RS, Mitzner W. A method of endotracheal intubation and pulmonary functional assessment for repeated studies in mice. J Appl Physiol 87: 2362–2365, 1999. [DOI] [PubMed] [Google Scholar]
- 12.Brusselle GG, Bracke KR, Maes T, D'hulst AI, Moerloose KB, Joos GF, Pauwels RA. Murine models of COPD. Pulm Pharmacol Ther 19: 155–165, 2006. [DOI] [PubMed] [Google Scholar]
- 13.Cantor JO, Shteyngart B, Cerreta JM, Liu M, Armand G, Turino GM. The effect of hyaluronan on elastic fiber injury in vitro and elastase-induced airspace enlargement in vivo. Proc Soc Exp Biol 225: 65–71, 2000. [DOI] [PubMed] [Google Scholar]
- 14.Cavarra E, Bartalesi B, Lucattelli M, Fineschi S, Lunghi B, Gambelli F, Ortiz LA, Martorana PA, Lungarella G. Effects of cigarette smoke in mice with different levels of α1-proteinase inhibitor and sensitivity to oxidants. Am J Respir Crit Care Med 164: 886–890, 2001. [DOI] [PubMed] [Google Scholar]
- 15.Chen JC, Brenner M, Kafie FE, Yoong B, Budd M, Gassel A, Waite TA, Millikan J, Huh J, Wang NS, McKenna R, Gelb A, Wilson AF, Bern MW. An animal model for lung volume reduction therapy of pulmonary emphysema. J Invest Surg 11: 129–137, 1998. [DOI] [PubMed] [Google Scholar]
- 16.Churg A, Cosio M, Wright JL. Mechanisms of cigarette smoke-induced COPD: insights from animal models. Am J Physiol Lung Cell Mol Physiol 294: L612–L631, 2008. [DOI] [PubMed] [Google Scholar]
- 17.Churg A, Tai H, Coulthard T, Wang R, Wright JL. Cigarette smoke drives small airway remodeling by induction of growth factors in the airway wall. Am J Respir Crit Care Med 174: 1327–1334, 2007. [DOI] [PubMed] [Google Scholar]
- 18.Churg A, Wang R, Wang X, Onnervik PO, Thim K, Wright JL. An MMP-9/-12 inhibitor prevents smoke-induced emphysema and small airway remodeling in guinea pigs. Thorax 62: 706–713, 2007. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 19.Churg A, Wang RD, Tai H, Wang X, Xie C, Wright JL. Tumor necrosis factor-α drives 70% of cigarette smoke-induced emphysema in the mouse. Am J Respir Crit Care Med 170: 492–498, 2004. [DOI] [PubMed] [Google Scholar]
- 20.Churg A, Wang X, Wang R, Meixner SC, Pryzdail EL, Wright JL. Alpha-1-antitrypsin suppresses TNF alpha and MMP-12 production by cigarette smoke-stimulated macrophages. Am J Respir Cell Mol Biol 37: 144–151, 2007. [DOI] [PubMed] [Google Scholar]
- 21.Cosio MG, Shiner RJ, Saetta M, Wang NS, King M, Ghezzo H, Angus E. Alveolar fenestrae in smokers. Am Rev Respir Dis 133: 126–131, 1986. [DOI] [PubMed] [Google Scholar]
- 22.Coxson HO, Chan IHT, Mayo JR, Hlynsky J, Nakano Y, Birmingham CL. Early emphysema in patients with anorexia nervosa. Am J Respir Crit Care Med 170: 748–752, 2004. [DOI] [PubMed] [Google Scholar]
- 23.Eidelman DH, Bellofiore S, Chiche D, Cosio MG, Martin JG. Behavior of morphometric indices in pancreatic elastase-induced emphysema in rats. Lung 168: 159–169, 1990. [DOI] [PubMed] [Google Scholar]
- 24.Fabbri L, Pauwels RA, Hurd SS, GOLD Scientific Committee. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD Executive Summary updated 2003. COPD 1: 105–141, 2003. [DOI] [PubMed] [Google Scholar]
- 25.Foronjy RF, Mercer BA, Maxfield MW, Powell CA, D'Armiento J. Structural emphysema does not correlate with lung compliance: lessons from the mouse smoking model. Exp Lung Res 31: 547–562, 2005. [DOI] [PubMed] [Google Scholar]
- 26.Foronjy RF, Mirochnitchenko O, Propokenko A, Lemaitre V, Jia Y, Inouye M, Okada Y, D'Armiento J. Superoxide dismutase expression attenuates cigarette smoke- or elastase-generated emphysema in mice. Am J Respir Crit Care Med 173: 623–631, 2006. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 27.Foronjy RF, Okada Y, Cole R, D'Armiento J. Progressive adult-onset emphysema in transgenic mice expressing human MMP-1 in the lung. J Appl Physiol 284: L727–L737, 2003. [DOI] [PubMed] [Google Scholar]
- 28.Gamze K, Mehmet HM, Deveci F, Turgut T, Ilhan F, Ozercan I. Effect of bosentan on the production of proinflammatory cytokines in a rat model of emphysema. Exp Mol Med 39: 614–620, 2007. [DOI] [PubMed] [Google Scholar]
- 29.Gan WQ, Man SF, Postma DS, Camp P, Sin DD. Female smokers beyond the perimenopausal period are at increased risk of chronic obstructive pulmonary disease: a systematic review and meta-analysis. Respir Res 7: 52–61, 2006. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 30.Gaschler GJ, Bauer CM, Zavitz CC, Stampfli MR. Animal models of chronic obstructive pulmonary disease exacerbations. Contrib Microbiol 14: 126–141, 2007. [DOI] [PubMed] [Google Scholar]
- 31.Gaworski CL, Dozier MM, Gerhart JM, Rajendran N, Brennecke LH, Aranyi C, Heck JD. 13-Week inhalation toxicity study of menthol cigarette smoke. Food Chem Toxicol 35: 683–692, 1997. [DOI] [PubMed] [Google Scholar]
- 32.Goco RV, Kress MB, Brantigan OC. Comparison of mucus glands in the tracheobronchial tree of man and animals. Ann NY Acad Sci 106: 555–571, 1963. [DOI] [PubMed] [Google Scholar]
- 33.Goldstein RH Response of the aging hamster lung to elastase injury. Am Rev Respir Dis 125: 295–298, 1982. [DOI] [PubMed] [Google Scholar]
- 34.Gross P, Pfitzer EA, Tolker E, Babyak MA, Kaschak M. Experimental emphysema: its production in normal and silicotic rats. Arch Environ Health 11: 50–58, 1965. [DOI] [PubMed] [Google Scholar]
- 35.Gudapaty SR, Liener IE, Hoidal JR, Padmanabhan RV, Niewoehner DE, Abel J. The prevention of elastase induced emphysema in hamsters by the intratracheal administration of a synthetic elastase inhibitor bound to albumin microspheres. Am Rev Respir Dis 132: 159–163, 1985. [DOI] [PubMed] [Google Scholar]
- 36.Guerassimov A, Hoshino M, Takubo Y, Turcotte A, Yamamoto M, Ghezzo H, Triantafillopoulos A, Whittaker K, Hoidal JR, Cosio MG. The development of emphysema in cigarette smoke-exposed mice is strain dependent. Am J Respir Crit Care Med 170: 974–980, 2005. [DOI] [PubMed] [Google Scholar]
- 37.Haas TL, Doyle JL, Distasi MR, Norton LE, Sheridan KM, Unthank JL. Involvement of MMPs in the outward remodeling of collateral mesenteric arteries. Am J Physiol Heart Circ Physiol 293: H2429–H2437, 2007. [DOI] [PubMed] [Google Scholar]
- 38.Halbert RJ, Natoli JL, Gano A, Badamqarav E, Buist AS, Mannino DM. Global burden of COPD: systematic review and meta-analysis. Eur Respir J 28: 523–532, 2006. [DOI] [PubMed] [Google Scholar]
- 39.Harber P, Tashkin DP, Simmons M, Crawford L, Hnizdo E, Connett J, Lung Health Study Group. Effect of occupational exposures on decline of lung function in early chronic obstructive pulmonary disease. Am J Respir Crit Care Med 176: 994–1000, 2007. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 40.Harkema JR, Hotchkiss JA. Ozone and endotoxin-induced mucous cell metaplasias in rat airway epithelium: novel animal models to study toxicant-induced epithelial transformation in airways. Toxicol Lett 68: 251–263, 1993. [DOI] [PubMed] [Google Scholar]
- 41.Harkema JR, Mauderly JL, Gregory RE, Pickrell JA. A comparison of starvation and elastase models of emphysema in the rat. Am Rev Respir Dis 129: 584–591, 1984. [PubMed] [Google Scholar]
- 42.Hayashi M, Sornberger GC, Huber GL. Differential response in the male and female tracheal epithelium following chronic tobacco smoke inhalation. Chest 4: 515–518, 1978. [DOI] [PubMed] [Google Scholar]
- 43.Heck JD, Gaworski CL, Rajendran N, Morrissey RL. Toxicologic evaluation of humectants added to cigarette tobacco: 13-week smoke inhalation study of glycerin and propylene glycol in Fischer 344 rats. Inhal Toxicol 14: 1135–1152, 2002. [DOI] [PubMed] [Google Scholar]
- 44.Henson PM, Vandivier RW. The matrix degrades, neutrophils invade. Nature Med 12: 280–281, 2006. [DOI] [PubMed] [Google Scholar]
- 45.Hislop A, Reid L. Normal structure and dimensions of the pulmonary arteries in the rat. J Anat 125: 71–83, 1978. [PMC free article] [PubMed] [Google Scholar]
- 46.Hogg JC Pathophysiology of airflow limitation in chronic obstructive pulmonary disease. Lancet 364: 709–721, 2004. [DOI] [PubMed] [Google Scholar]
- 47.Hogg JC, Chu F, Utokaparch S, Woods R, Elliott WM, Buzatu L, Cherniack RM, Rogers RM, Sciurba FC, Coxson HO, Pare PD. The nature of small-airway obstruction in chronic obstructive pulmonary disease. N Engl J Med 350: 2645–2653, 2004. [DOI] [PubMed] [Google Scholar]
- 48.Houghton AM, Quintero PA, Perkins DL, Kobayashi DK, Kelley DG, Marconcini LA, Mecham RP. Elastin fragments drive disease progression in a murine model of emphysema. J Clin Invest 116: 753–759, 2006. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 49.Ishikawa T, Aoshiba K, Yokohori N, Nagai A. Macrophage colony-stimulating factor aggravates rather than regenerates emphysematous lungs in mice. Respiration 73: 538–545, 2006. [DOI] [PubMed] [Google Scholar]
- 50.Ishizawa K, Kubo H, Yamada M, Kobayashi S, Numasaki M, Ueda S, Suzuki T, Sasaki H. Bone marrow-derived cells contribute to lung regeneration after elastase-induced pulmonary emphysema. FEBS Lett 556: 249–252, 2004. [DOI] [PubMed] [Google Scholar]
- 51.Ito S, Ingenito EP, Brewer KK, Black LD. Mechanics, nonlinearity, and failure strength of lung tissue in a mouse model of emphysema: possible role of collagen remodeling. J Appl Physiol 98: 503–511, 2005. [DOI] [PubMed] [Google Scholar]
- 52.Janoff A Elastases and emphysema. Am Rev Respir Dis 132: 417–433, 1985. [DOI] [PubMed] [Google Scholar]
- 53.Janoff A, White R, Carp H, Harel S, Dearing R, Lee D. Lung injury induced by leukocytic proteases. Am J Pathol 97: 111–136, 1979. [PMC free article] [PubMed] [Google Scholar]
- 54.Jeffery PK Morphologic features of airway surface epithelial cells and glands. Am Rev Respir Dis 128: S14–S20, 1983. [DOI] [PubMed] [Google Scholar]
- 55.Jeffery PK, Reid LM. The respiratory mucous membrane. In: Respiratory Defense Mechanisms Part 1, edited by Brain JD, Proctor DF, and Reid LM. New York: Dekker, 1977, p. 193–245.
- 56.Johanson WG, Pierce AK. Lung structure and function with age in normal rats and rats with papain emphysema. J Clin Invest 52: 2921–2927, 1973. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 57.Jones R, Dolduc P, Reid L. Protection of rat bronchial epithelium against tobacco smoke. Br Med J 2: 142–144, 1972. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 58.Kaplan PD, Kuhn C, Pierce JA. The induction of emphysema with elastase. I. The evolution of the lesion and the influence of serum. J Lab Clin Med 82: 349–356, 1973. [PubMed] [Google Scholar]
- 59.Karlinsky JB, Goldstein RH, Catanese A, Snider GL. Young hamsters are more resistant than adults to endotracheally instilled porcine pancreastic elastase. Exp Lung Res 11: 229–243, 1986. [DOI] [PubMed] [Google Scholar]
- 60.Kasahara Y, Tuder RM, Taraseviciene-Stewart L, Le Cras TD, Abman S, Hirth PK, Waltenberger J, Voelkel NF. Inhibition of VEGF receptors causes lung cell apoptosis and emphysema. J Clin Invest 106: 1311–1319, 2000. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 61.Kawakami M, Paul JL, Thurlbeck WM. The effect of age on lung structure in male BALB/cNNia inbred mice. Am J Anat 170: 1–21, 1984. [DOI] [PubMed] [Google Scholar]
- 62.Kharitonov SA, Sjobring U. Lipopolysaccharide challenge of humans as a model for chronic obstructive lung disease exacerbations. Contrib Microbiol 14: 83–100, 2007. [DOI] [PubMed] [Google Scholar]
- 63.Kleinerman J, Ranga V, Rynbrandt D, Sorensen J, Powers JC. The effect of the specific elastase inhibitor, alanyl alanyl prolyl alanine chloromethylketone, on elastase-induced emphysema. Am Rev Respir Dis 121: 381–387, 1980. [DOI] [PubMed] [Google Scholar]
- 64.Kuhn C, Homer RJ, Zhu Z, Ward N, Flavell RA, Geba GP, Elias JA. Airway hyperresponsiveness and airway obstruction in transgenic mice: morphologic correlates in mice overexpressing interleukin (IL)-11 and IL-6 in the lung. Am J Respir Cell Mol Biol 22: 289–295, 2000. [DOI] [PubMed] [Google Scholar]
- 65.Kuhn C, Tavassoli F. The scanning electron microscopy of elastase-induced emphysema. Lab Invest 34: 2–9, 1976. [PubMed] [Google Scholar]
- 66.Kuhn C, Yu SY, Chraplyvy M, Linder HE, Senior RM. The induction of emphysema with elastase. II. Changes in connective tissue. Lab Invest 34: 372–380, 1976. [PubMed] [Google Scholar]
- 67.Lafuma C, Frisdal E, Harf A, Robert L, Hornebeck W. Prevention of leucocyte elastase-induced emphysema in mice by heparin fragments. Eur Respir J 4: 1005–1009, 1991. [PubMed] [Google Scholar]
- 68.Lai YL, Diamond L. Inhibition of porcine pancreatic elastase-induced emphysema by eglin-c. Exp Lung Res 16: 547–557, 1990. [DOI] [PubMed] [Google Scholar]
- 69.Lamb D, Reid L. Goblet cell increase in rat bronchial epithelium after expsoure to cigarette and cigar tobacco smoke. Br Med J 1: 33–35, 2001. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 70.Langhammer A, Johnsen R, Gulsvik A, Holmen TL, Bjermer L. Sex differences in lung vulnerability to tobacco smoking. Eur Respir J 21: 1017–1023, 2003. [DOI] [PubMed] [Google Scholar]
- 71.Laurell CB, Eriksson S. The electrophoretic a1-globulin pattern of serum in a1-antitrypsin deficiency. Scand J Clin Lab Invest 15: 132–140, 1963. [Google Scholar]
- 72.Lee JH, Lee DS, Kim EK, Choe KH, Oh YM, Shim TS, Kim SE, Lee YS, Lee SD. Simvastatin inhibits cigarette smoking-induced emphysema and pulmonary hypertension in rat lungs. Am J Respir Crit Care Med 172: 987–993, 2005. [DOI] [PubMed] [Google Scholar]
- 73.Lee KM, Renne RA, Harbo SJ, Clark ML, Johnson RE, Gideon KM. 3-Week inhalation exposure to cigarette smoke and/or lipopolysaccharide in AKR/1 mice. Inhal Toxicol 19: 23–35, 2007. [DOI] [PubMed] [Google Scholar]
- 74.Lesser M, Padilla ML, Cardozo C. Induction of emphysema in hamsters by intratracheal instillation of cathepsin B. Am Rev Respir Dis 145: 661–668, 1992. [DOI] [PubMed] [Google Scholar]
- 75.Lieberman J Elastase collagenase emphysema and alpha-1-antitrypsin deficiency. Chest 70: 62–67, 1976. [DOI] [PubMed] [Google Scholar]
- 76.Lucey EC, Goldstein RH, Breuer R, Rexer BN, Ong DE, Snider GL. Retinoic acid does not affect alveolar septation in adult FVB mice with elastase-induced emphysema. Respiration 70: 200–205, 2003. [DOI] [PubMed] [Google Scholar]
- 77.Lucey EC, Goldstein RH, Stone PJ, Snider GL. Remodeling of alveolar walls after elastase treatment of hamsters. Results of elastin and collagen mRNA in situ hybridization. Am J Respir Crit Care Med 158: 555–564, 1998. [DOI] [PubMed] [Google Scholar]
- 78.Lucey EC, Keane J, Kuang PP, Snider GL, Goldstein RH. Severity of elastase-induced emphysema is decreased in tumor necrosis factor-α and interleukin-1β receptor-deficient mice. Lab Invest 82: 79–85, 2002. [DOI] [PubMed] [Google Scholar]
- 79.Lucey EC, Stone PJ. Effect of chloromethyl ketone on the progression of elastase induced emphysema in hamsters. Am Rev Respir Dis 126: 174–175, 1982. [DOI] [PubMed] [Google Scholar]
- 80.Lungarella G, Gardi C, Fonzi L, Comparini L, Share NN, Zimmerman M, Martorana PA. Effect of the novel synthetic protease inhibitor furoyl saccharin on elastase-induced emphysema in rabbits and hamsters. Exp Lung Res 11: 35–47, 1986. [DOI] [PubMed] [Google Scholar]
- 81.Maeno T, Houghton AM, Quinton PM, Grumelli S, Owen CA, Shapiro SD. CD8+ T cells are required for inflammation and destruction in cigarette smoke-induced emphysema in mice. J Immunol 178: 8090–8096, 2007. [DOI] [PubMed] [Google Scholar]
- 82.Mahadeva R, Shapiro SD. Chronic obstructive pulmonary disease 3: experimental animal models of pulmonary emphysema. Thorax 57: 914, 2002. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 83.Mallia P, Johnston SL. Mechanisms and experimental models of chronic obstructive pulmonary disease exacerbations. Proc Am Thorac Soc 2: 361–366, 2005. [DOI] [PubMed] [Google Scholar]
- 84.March TH, Wilder JA, Esparza DC, Cossey PY, Blair LF, Herrera LK, McDonald JD, Campen MJ, Mauderly JL, Seagrave J. Modulators of cigarette smoke-induced pulmonary emphysema in A/J mice. Toxicology 92: 545–559, 2006. [DOI] [PubMed] [Google Scholar]
- 85.Martinez FJ, Curtis JL, Sciurba F, Mymford J, Giardino ND, Weinmann G, Kazerooni E, Murray S, Criner GJ, Sin DD, Hogg JC, Ries AL, Han M, Fishman AP, Make G, Hoffman EA, Mohsenifar Z, Wise R, National Emphysema Treatment Trial Research Group. Sex differences in severe pulmonary emphysema. Am J Respir Crit Care Med 176: 243–252, 2007. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 86.Martorana PA, Share NN. Effect of human alpha-antitrypsin on papain induced emphysema in the hamster. Am Rev Respir Dis 113: 607–612, 1976. [DOI] [PubMed] [Google Scholar]
- 87.Martorana PA, Van Even P, Schaper J. The effect of lung growth on the evolution of elastase-induced emphysema in the hamster. Lung 160: 19–27, 1982. [Google Scholar]
- 88.Marwick JA, Stevenson CS, Giddings J, MacNee W, Butler K, Rahman I, Kirkham PA. Cigarette smoke disrupts the VEGF165-VEGFR2 receptor signaling complex in rat lungs and patients with COPD: morphological impact of VEGFR2 inhibition. Am J Physiol Lung Cell Mol Physiol 290: L897–L908, 2006. [DOI] [PubMed] [Google Scholar]
- 89.Massaro D, Alexander E, Reiland K, Hoffman EP, Massaro GD, Clerch LB. Rapid onset of gene expression in lung, supportive of formation of alveolar septa, induced by refeeding mice after calorie restriction. Am J Physiol Lung Cell Mol Physiol 292: L1313–L1326, 2007. [DOI] [PubMed] [Google Scholar]
- 90.Massaro D, Massaro GD. Developmental alveologenesis: longer, differential regulation and perhaps more danger. Am J Physiol Lung Cell Mol Physiol 293: L568–L569, 2007. [DOI] [PubMed] [Google Scholar]
- 91.Massaro D, Massaro GD, Baras A, Hoffman EP, Clerch LB. Calorie-related rapid onset of alveolar loss, regeneration, and changes in mouse lung gene expression. Am J Physiol Lung Cell Mol Physiol 286: L896–L906, 2004. [DOI] [PubMed] [Google Scholar]
- 92.Mauderly JL, Bechtold WE, Bond JA, Brooks AL, Chen BT, Cuddihy RG, Harkema JR, Henderson RF, Johnson NF, Rithidech K, Thomassen DG. Comparison of 3 methods of exposing rats to cigarette smoke. Exp Pathol 37: 194–197, 1989. [PubMed] [Google Scholar]
- 93.McBride JT Architecture of the Tracheobronchial Tree. In: Comparative Biology of the Normal Lung, edited by Parent RA. Boca Raton: CRC, 1991, p. 49–62.
- 94.McLaughlin RF, Tyler WS, Canada RO. Subgross pulmonary anatomy of the rabbit, rat, and guinea pig, with additional notes on the human lung. Am Rev Respir Dis 94: 380–387, 1966. [DOI] [PubMed] [Google Scholar]
- 95.Min MG, Song DJ, Miller M, Cho JY, McElwain S, Ferguson P, Broide DH. Coexposure to environmental tobacco smoke increases levels of allergen-induced airway remodeling in mice. J Immunol 178: 5321–5328, 2007. [DOI] [PubMed] [Google Scholar]
- 96.Morio Y, Muramatsu M, Takahashi K, Teramoto S, Oka T, Fukuchi Y. Distal airspace enlargement in the fawn-hooded rat: influences of aging and alveolar wall destruction. Respiration 68: 78–86, 2001. [DOI] [PubMed] [Google Scholar]
- 97.Morris DG, Huang X, Kaminski N, Wang Y, Shapiro SD, Dolganov G, Glick A, Sheppard D. Loss of integrin αvβ6-mediated TGF-β activation causes Mmp12-dependent emphysema. Nature 422: 169–173, 2003. [DOI] [PubMed] [Google Scholar]
- 98.Mullen JBM, Wright JL, Wiggs BR, Pare PD, Hogg JC. Structure of central airways in current smokers and ex-smokers with and without mucus hypersecretion: relationship to lung function. Thorax 42: 843–848, 1987. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 99.Murray JF The Normal Lung: The Basis for Diagnosis and Treatment of Pulmonary Disease. Philadelphia, PA: Saunders, 1976.
- 100.Nadziejko C, Fang K, Bravo A, Gordon T. Susceptibility to pulmonary hypertension in inbred strains of mice exposed to cigarette smoke. J Appl Physiol 102: 1780–1785, 2007. [DOI] [PubMed] [Google Scholar]
- 101.Nagai A, Inano H, Matsuba K, Thurlbeck WM. Scanning electron microscopic morphometry of emphysema in humans. Am J Respir Crit Care Med 150: 1411–1415, 1994. [DOI] [PubMed] [Google Scholar]
- 102.Nishi Y, Boswell V, Ansar T, Piprawala F, Satchi S, Page CP. Elastase-induced changes in lung function: relationship to morphometry and effect of drugs. Pulm Pharmacol Ther 16: 221–229, 2003. [DOI] [PubMed] [Google Scholar]
- 103.Obot CJ, Lee KM, Fuciarelli AF, Renne RA, McKinney WJ. Characterization of mainstream cigarette smoke-induced biomarker responses in ICR and C57Bl/6 mice. Inhal Toxicol 16: 701–719, 2004. [DOI] [PubMed] [Google Scholar]
- 104.Pack RH, Al-Ugaily LH, Morris G, Widdicombe JG. The distribution and structure of cells in the tracheal epithelium of the mouse. Cell Tis Res 208: 65–84, 1980. [DOI] [PubMed] [Google Scholar]
- 105.Pack RJ, Al-Ugaily LH, Morris G. The cells of the tracheobronchial epithelium of the mouse: a quantitative light and electron microscope study. J Anat 132: 71–84, 1981. [PMC free article] [PubMed] [Google Scholar]
- 106.Paddenberg R, Konig P, Faulhammer P, Goldenberg A, Pfeil U, Kummer W. Hypoxic vasoconstriction of partial muscular intra-acinar pulmonary arteries in murine precision cut lung slices. Respir Res 7: 93–110, 2006. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 107.Pare PD, Wiggs BR, James A, Hogg JC, Bosken CH. The comparative mechanics and morphology of airways in asthma and in chronic obstructive pulmonary disease. Am Rev Respir Dis 143: 1189–1193, 1991. [DOI] [PubMed] [Google Scholar]
- 108.Park SS, Kikkawa Y, Goldring IP, Daly MM, Zelefsky M, Shim C, Spierer M, Morita T. An animal model of cigarette smoking in beagle dogs. Am Rev Respir Dis 115: 971–979, 1977. [DOI] [PubMed] [Google Scholar]
- 109.Pauwels RA, Rabe KF. Burden and clinical features of chronic obstructive pulmonary disease. Lancet 364: 613–620, 2004. [DOI] [PubMed] [Google Scholar]
- 110.Petrache I, Fijalkowsak I, Medler TR, Skirball J, Cruz P, Zhen L, Petrache HI, Flotte TR, Tuder RM. α-1 Antitrypsin inhibits caspase-3 activity, preventing lung endothelial cell apoptosis. Am J Pathol 169: 1155–1166, 2006. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 111.Petrache I, Natarajan V, Zhen L, Medler TR, Richter AT, Cho C, Hubbard WC, Berdyshev EV, Tuder RM. Ceramide upregulation causes pulmonary cell apoptosis and emphysema-like disease in mice. Nature Med 11: 491–498, 2005. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 112.Pinkerton KE, Dodge DE, Cederdahl-Demmier J, Wong VJ, Peake J, Haselton CJ, Mellick PW, Singh G, Plopper CG. Differentiated bronchiolar epithelium in alveolar ducts of rats exposed to ozone for 20 months. Am J Pathol 142: 947–956, 1992. [PMC free article] [PubMed] [Google Scholar]
- 113.Plopper CG, Hill LH, Mariassy AT. Ultrastructure of the nonciliated bronchiolar epithelial (Clara) cell of mammalian lung. III. A study of man with comparison of 15 mammalian species. Exp Lung Res 1: 171–180, 1980. [DOI] [PubMed] [Google Scholar]
- 114.Plopper CG, Mariassy AT, Hill LH. Ultrastructure of the nonciliated bronchiolar epithelial (Clara) cell of mammalian lung: I. A comparison of rabbit guinea pig rat hamster and mouse. Exp Lung Res 1: 139–154, 1980. [DOI] [PubMed] [Google Scholar]
- 115.Rabe KF, Hurd S, Anzueto A, Barnes PJ, Buist SA, Calverley P, Fukuchi Y, Jenkins C, Rodriguez-Roisin R, van Weel C, Zielinski J. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med 176: 532–555, 2007. [DOI] [PubMed] [Google Scholar]
- 116.Ravnic DJ, Konerding MA, Pratt JP, Wolloscheck T, Huss HT, Mentzer SJ. The murine bronchopulmonary microcirculation in hapten-induced inflammation. J Thorac Cardiovasc Surg 133: 97–103, 2007. [DOI] [PubMed] [Google Scholar]
- 117.Rogers DF, Jeffery PK. Inhibition by oral N-acteylcysteine of cigarette smoke-induced “bronchitis” in the rat. Exp Lung Res 10: 267–283, 1986. [DOI] [PubMed] [Google Scholar]
- 118.Rudolphus A, Stolk J, Dijkman JH, Kramps JA. Inhibition of lipopolysaccharide induced pulmonary emphysema by intratracheally instilled recombinant secretory leukocyte proteinase inhibitor. Am Rev Respir Dis 147: 442–447, 1993. [DOI] [PubMed] [Google Scholar]
- 119.Sahebjami H Effects of postnatal starvation and refeeding on rat lungs during adulthood. Am Rev Respir Dis 133: 769–772, 1986. [PubMed] [Google Scholar]
- 120.Sahebjami H, Domino M. Effects of repeated cycles of starvation and refeeding on lungs of growing rats. J Appl Physiol 73: 2349–2354, 1992. [DOI] [PubMed] [Google Scholar]
- 121.Sahebjami H, MacGee J. Effects of starvation and refeeding on lung biochemistry in rats. Am Rev Respir Dis 126: 483–487, 1982. [DOI] [PubMed] [Google Scholar]
- 122.Sahebjami H, MacGee J. Changes in connective tissue composition of the lung in starvation and refeeding. Am Rev Respir Dis 128: 644–647, 1983. [DOI] [PubMed] [Google Scholar]
- 123.Sahebjami H, Vassallo CL. Effects of starvation and refeeding on lung mechanics and morphometry. Am Rev Respir Dis 119: 443–451, 1979. [DOI] [PubMed] [Google Scholar]
- 124.Sahebjami H, Vassallo CL, Wirman JA. Lung mechanics and ultrastructure in prolonged starvation. Am Rev Respir Dis 117: 77–83, 1978. [DOI] [PubMed] [Google Scholar]
- 125.Sahebjami H, Wirman JA. Emphysema-like changes in the lungs of starved rats. Am Rev Respir Dis 124: 619–624, 1981. [DOI] [PubMed] [Google Scholar]
- 126.Sawada M, Ohno Y, La BL, Funaguchi N, Asai T, Yuhgetsu H, Takemura G, Minatoguchi S, Fujiwara H, Fujiwara T. The Fas/Fas-ligand pathway does not mediate the apoptosis in elastase-induced emphysema in mice. Exp Lung Res 33: 277–288, 2007. [DOI] [PubMed] [Google Scholar]
- 127.Seong MW, Nam MH, Ryu HJ, Kong SY, Myung SK, Seo HG, Shin HR, Park JG, Lee DH. The comparison of two smoking biomarkers in various biological samples. Clin Chim Acta 383: 180–181, 2007. [DOI] [PubMed] [Google Scholar]
- 128.Shapiro SD Animal models for chronic obstructive pulmonary disease. Am J Respir Cell Mol Biol 22: 4–7, 2000. [DOI] [PubMed] [Google Scholar]
- 129.Shinohara T, Kaneko T, Nagashima Y, Ueda A, Tagawa A, Ishigatsubo Y. Adenovirus-mediated transfer and overexpression of heme oxygenase 1 cDNA in lungs attenuates elastase-induced pulmonary emphysema in mice. Hum Gene Ther 16: 318–327, 2005. [DOI] [PubMed] [Google Scholar]
- 130.Sisson TH, Hansen JM, Shah M, Hanson KE, Du M, Ling T, Simon RH, Christensen PJ. Expression of the reverse tetracycline-transactivator gene causes emphysema-like changes in mice. Am J Respir Cell Mol Biol 34: 552–560, 2006. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 131.Stang P, Lydick E, Silberman C, Kempel A, Keating ET. The prevalence of COPD: using smoking rates to estimate disease frequency in the general population. Chest 117: 354S–359S, 2000. [DOI] [PubMed] [Google Scholar]
- 132.Stevenson CS, Doex C, Webster R, Battram C, Hynx D, Giddings J, Cooper PR, Chakravarty P, Rahman I, Marwick JA, Kirkham PA, Charman C, Richardson DL, Nirmala NR, Whittaker P, Butler K. Comprehensive gene expression profiling of rat lung reveals distinct acute and chronic responses to cigarette smoke inhalation. Am J Physiol Lung Cell Mol Physiol 293: L1183–L1193, 2007. [DOI] [PubMed] [Google Scholar]
- 133.Stone PJ, Lucey EC, Calore JD, McMahon MP, Snider GL, Franzblau C. Defenses of the hamster lung against human neutrophil and porcine pancreatic elastase. Respiration 54: 1–15, 1988. [DOI] [PubMed] [Google Scholar]
- 134.Stone PJ, Lucey EC, Calore JD, Snider GL, Franzblau C, Castillo MJ, Powers JC. The moderation of elastase-induced emphysema in the hamster by intratracheal pretreatment or post-treatment with succinyl alanyl alanyl prolyl valine chloromethyl ketone. Am Rev Respir Dis 124: 56–59, 1981. [DOI] [PubMed] [Google Scholar]
- 135.Suzuki T, Kasai T. Morphological and embryological characteristics of bronchial arteries in the rat. Anat Embryol 207: 95–99, 2003. [DOI] [PubMed] [Google Scholar]
- 136.Takamoto M, Miyazaki N, Ishibashi T, Sugiyama K. Protease-induced experimental emphysema: the relationship between elastolytic activity and emphysema induction. Jpn J Exp Med 48: 419–425, 1978. [PubMed] [Google Scholar]
- 137.Takubo Y, Guerassimov A, Ghezzo H, Triantafillopoulos A, Bates JHT, Hoidal JR, Cosio MG. α1-Antitrypsin determines the pattern of emphysema and function in tobacco smoke-exposed mice. Parallels with human disease. Am J Respir Crit Care Med 166: 1596–1603, 2002. [DOI] [PubMed] [Google Scholar]
- 138.Taraseviciene-Stewart L, Kasahara Y, Alger L, Hirth P, McMahon G, Waltenberger J, Voelkel NF, Tuder RM. Inhibition of the VEGF receptor 2 combined with chronic hypoxia causes cell death-dependent pulmonary endothelial cell proliferation and severe pulmonary hypertension. FASEB J 15: 427–438, 2001. [DOI] [PubMed] [Google Scholar]
- 139.Taraseviciene-Stewart L, Scerbavicius R, Choe KH, Moore M, Sullivan A, Nicolls MR, Fontenot AP, Tuder RM, Veolkel NF. An animal model of autoimmune emphysema. Am J Respir Crit Care Med 171: 734–742, 2005. [DOI] [PubMed] [Google Scholar]
- 140.Tarnavski O, McMullen JR, Schinke M, Nie Q, Kong S, Izumo S. Mouse cardiac surgery: comprehensive techniques for the generation of mouse models of human diseases and their application for geomic studies. Physiol Genomics 16: 349–360, 2004. [DOI] [PubMed] [Google Scholar]
- 141.Thurlbeck WM Christie Lecture: emphysema then and now. Can Respir J 1: 21–39, 1994. [Google Scholar]
- 142.Toward TJ, Broadley KJ. Goblet cell hyperplasia, airway function, and leukocyte infiltration after chronic lipopolysaccharide exposure in conscious guinea pigs: effects of rolipram and dexamethasone. Pharm Exp Ther 302: 814–821, 2002. [DOI] [PubMed] [Google Scholar]
- 143.Tuder RM, Cool CD, Yeager M, Taraseviciene-Stewart L, Bull TM, Voelkel NF. The pathobiology of pulmonary hypertension. Clin Chest Med 22: 405–418, 2001. [DOI] [PubMed] [Google Scholar]
- 144.Tuder RM, McGrath S, Neptune E. The pathobiological mechanisms of emphysema models: what do they have in common? Pulm Pharmacol Ther 16: 67–78, 2003. [DOI] [PubMed] [Google Scholar]
- 145.Tuder RM, Petrache I, Elias JA, Voelkel NF, Henson PM. Apoptosis and emphysema: the missing link. Am J Respir Cell Mol Biol 28: 551–554, 2003. [DOI] [PubMed] [Google Scholar]
- 146.van der Strate BW, Postma DA, Brandsma CA, Melgert BN, Luinge MA, Geerlings M, Hylkema MN, vander Berg A, Timens W, Kerstjens HAM. Cigarette smoke-induced emphysema: a role for the B cell? Am J Respir Crit Care Med 173: 751–758, 2006. [DOI] [PubMed] [Google Scholar]
- 147.Vernooy JHJ, Dentener MA, van Suylen RJ, Buurman WA, Wouters EFM. Long-term intratracheal lipopolysaccharide exposure in mice results in chronic lung inflammation and persistent pathology. Am J Respir Cell Mol Biol 26: 152–159, 2002. [DOI] [PubMed] [Google Scholar]
- 148.Viegi G, Scognamiglio A, Baldacci S, Pistelli F, Carrozzi L. Epidemiology of chronic obstructive pulmonary disease (COPD). Respiration 68: 4–19, 2001. [DOI] [PubMed] [Google Scholar]
- 149.Vlahos R, Bozinovski S, Gualano RC, Ernst M, Anderson GP. Modelling COPD in mice. Pulm Pharmacol Ther 19: 12–17, 2006. [DOI] [PubMed] [Google Scholar]
- 150.Voelkel NF, Cool C, Taraceviene-Stewart L, Geraci MW, Yeager M, Bull T, Kasper M, Tuder RM. Janus face of vascular endothelial growth factor: the obligatory survival factor for lung vascular endothelium controls precapillary artery remodeling in severe pulmonary hypertension. Crit Care Med 30: S251–S256, 2002. [DOI] [PubMed] [Google Scholar]
- 151.Voelkel NF, Vandivier RW, Tuder RM. Vascular endothelial growth factor in the lung. Am J Physiol Lung Cell Mol Physiol 290: L209–L221, 2006. [DOI] [PubMed] [Google Scholar]
- 152.Widdicombe JH, Chen LLK, Sporer H, Choi HK, Pecson IS, Bastacky SJ. Distribution of tracheal and laryngeal mucous glands in some rodents and the rabbit. J Anat 198: 207–221, 2001. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 153.Williams JC, Falcone RC, Knee C, Stein RL, Strimpler AM, Reaves B, Giles RE, Krell RD. Biologic characterization of ICI 200,880 and ICI 200,355, novel inhibitors of human neutrophil elastase. Am Rev Respir Dis 144: 875–883, 1991. [DOI] [PubMed] [Google Scholar]
- 154.Wright JL The importance of ultramicroscopic emphysema in cigarette smoke induced lung disease. Lung 179: 71–81, 2001. [DOI] [PubMed] [Google Scholar]
- 155.Wright JL, Churg A. Cigarette smoke causes physiologic and morphologic changes of emphysema in the guinea pig. Am Rev Respir Dis 142: 1422–1428, 1990. [DOI] [PubMed] [Google Scholar]
- 156.Wright JL, Lawson LM, Kennedy S, Wiggs B, Hogg JC. The detection of small airways disease. Am Rev Respir Dis 129: 989–994, 1984. [DOI] [PubMed] [Google Scholar]
- 157.Wright JL, Levy RD, Churg A. Pulmonary hypertension in chronic obstructive pulmonary disease: current theories of pathogenesis and their implications for treatment. Thorax 60: 605–609, 2005. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 158.Wright JL, Ngai T, Churg A. Effect of long-term exposure to cigarette smoke on the small airways of the guinea pig. Exp Lung Res 18: 105–114, 1992. [DOI] [PubMed] [Google Scholar]
- 159.Wright JL, Postma DS, Kerstjens HAM, Timens W, Whittaker P, Churg A. Airway remodeling in the smoke exposed guinea pig model. Inhal Toxicol 19: 915–923, 2007. [DOI] [PubMed] [Google Scholar]
- 160.Wright JL, Sun JP. The effect of smoking cessation on pulmonary and cardiovascular function and structure. J Appl Physiol 76: 2163–2168, 1994. [DOI] [PubMed] [Google Scholar]
- 161.Wright JL, Sun JP, Vedal S. A longitudinal analysis of pulmonary function in rats during a 12 month cigarette smoke exposure. Eur Respir J 10: 1115–1119, 1997. [DOI] [PubMed] [Google Scholar]
- 162.Wright JL, Tai H, Churg A. Vasoactive mediators and pulmonary hypertension after cigarette smoke exposure in the guinea pig. J Appl Physiol 100: 672–678, 2006. [DOI] [PubMed] [Google Scholar]
- 163.Yoshida T, Tuder RM. Pathobiology of chronic obstructive pulmonary disease. Physiol Rev 87: 1047–1082, 2007. [DOI] [PubMed] [Google Scholar]
- 164.Yuhgetsu H, Ohno Y, Funaguchi N, Asai T, Sawada M, Takemura G, Minatoguchi S, Fujiwara H, Fujiwara T. Beneficial effects of autologous bone marrow mononuclear cell transplantation against elastase-induced emphysema in rabbits. Exp Lung Res 32: 413–426, 2006. [DOI] [PubMed] [Google Scholar]
- 165.Zapletal A, Houstek J, Samanek M, Vavrova V, Srajer J. Lung function abnormalities in cystic fibrosis and changes during growth. Bull Eur Physiopath Respir 15: 575–592, 1979. [PubMed] [Google Scholar]
- 166.Zhu Z, Lee CG, Zheng T, Chupp G, Wang J, Homer RJ, Noble PW, Hamid Q, Elias JA. Airway inflammation and remodeling in asthma. Am J Respir Crit Care Med 164: 567–570, 2001. [DOI] [PubMed] [Google Scholar]









